US BROKER MOVES: DG upgraded at HSBC; CRWV upgraded at JPM

A routine morning broker sweep, but with two discernible patterns rather than pure noise.

Newsquawk StaffPublished On the live feed at , 20 minutes before this page
Newsquawk headlinesUTC

US BROKER MOVES: DG upgraded at HSBC; CRWV upgraded at JPM

BlackRock (BLK) has built three investment portfolios that will trade as digital tokens, WSJ reports

Lowe's (LOW) is launching a drone delivery service in partnership with DoorDash (DASH) and Alphabet (GOOGL), reports CNBC

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.

UPGRADES

  • Welltower (WELL) upgraded from Neutral to Overweight at JPMorgan; PT USD 260.00
  • Synopsys (SNPS) upgraded from Underperform to Neutral at BNP Paribas Exane
  • Quanta Services (PWR) upgraded from Market Perform to Outperform at Bernstein SocGen Group; PT USD 775.00 (prev. USD 748.00)
  • Paychex (PAYX) upgraded from Underweight to Neutral at JPMorgan; PT USD 115.00 (prev. USD 105.00)
  • Nebius Group (NBIS) upgraded from Neutral to Outperform at BNP Paribas Exane; PT USD 399.00 (prev. USD 260.00)
  • Macerich (MAC) upgraded from Neutral to Overweight at JPMorgan; PT USD 26.00
  • EastGroup Properties (EGP) upgraded from Neutral to Overweight at JPMorgan; PT USD 231.00
  • Dollar General (DG) upgraded from Hold to Buy at HSBC; PT USD 160.00
  • CoreWeave (CRWV) upgraded from Neutral to Overweight at JPMorgan; PT USD 125.00
  • Americold Realty Trust (COLD) upgraded from Underweight to Neutral at JPMorgan; PT USD 16.00
  • Arcturus Therapeutics (ARCT) upgraded from Neutral to Buy at Citi; PT USD 20.00 (prev. USD 8.00)

DOWNGRADES

  • Yum! Brands (YUM) downgraded from Buy to Hold at Argus
  • VICI Properties (VICI) downgraded from Overweight to Neutral at JPMorgan; PT USD 30.00
  • Tanger (SKT) downgraded from Overweight to Neutral at JPMorgan; PT USD 39.00
  • Stitch Fix (SFIX) downgraded from Outperform to Market Perform at William Blair
  • Safehold (SAFE) downgraded from Neutral to Underweight at JPMorgan; PT USD 14.00
  • Rollins (ROL) downgraded from Overweight to Neutral at Piper Sandler; PT USD 33.00 (prev. USD 46.00)
  • Kite Realty Group Trust (KRG) downgraded from Neutral to Underweight at JPMorgan; PT USD 27.00
  • Gaming and Leisure Properties (GLPI) downgraded from Overweight to Neutral at JPMorgan; PT USD 46.00
  • Etsy (ETSY) downgraded from Buy to Neutral at Arete; PT USD 81.00
  • Dropbox (DBX) downgraded from Neutral to Sell at Citi; PT USD 29.00 (prev. USD 33.00)
  • Alexandria Real Estate Equities (ARE) downgraded from Neutral to Underweight at JPMorgan; PT USD 56.00
  • Alkami Technology (ALKT) downgraded from Overweight to Underweight at JPMorgan; PT USD 14.00 (prev. USD 24.00)

INITIATIONS

  • Wintrust Financial (WTFC) initiated Equal Weight at Wells Fargo; PT USD 160.00
  • Versant (VSNT) initiated Buy at Citi; PT USD 41.00
  • United Therapeutics (UTHR) initiated Sell at Goldman Sachs; PT USD 321.00
  • Tarsus Pharmaceuticals (TARS) initiated Buy at Goldman Sachs; PT USD 116.00
  • Sagimet Biosciences (SGMT) initiated Sell at Goldman Sachs; PT USD 7.00
  • Revolution Medicines (RVMD) initiated Buy at Goldman Sachs; PT USD 267.00
  • Quince Therapeutics (QNCX) initiated Buy at Rodman & Renshaw; PT USD 70.00
  • PubMatic (PUBM) initiated Buy at Craig-Hallum; PT USD 24.00
  • Old National Bancorp (ONB) initiated Overweight at Wells Fargo; PT USD 30.00
  • MeiraGTx (MGTX) initiated Neutral at Goldman Sachs; PT USD 16.00
  • MGM Resorts International (MGM) initiated Neutral at BofA Securities; PT USD 40.00
  • MGE Energy (MGEE) initiated Neutral at BofA Securities; PT USD 76.00
  • Madrigal Pharmaceuticals (MDGL) initiated Buy at Goldman Sachs; PT USD 704.00
  • Kymera Therapeutics (KYMR) initiated Early-Stage Biotech at Goldman Sachs
  • Krystal Biotech (KRYS) initiated Buy at Goldman Sachs; PT USD 441.00
  • Kodiak Sciences (KOD) initiated Neutral at Goldman Sachs; PT USD 36.00
  • Jazz Pharmaceuticals (JAZZ) initiated Buy at Goldman Sachs; PT USD 337.00
  • Iovance Biotherapeutics (IOVA) initiated Buy at Goldman Sachs; PT USD 15.00
  • Insmed (INSM) initiated Buy at Goldman Sachs; PT USD 188.00
  • IMAX (IMAX) initiated Overweight at Morgan Stanley; PT USD 63.00
  • Fervo Energy (FRVO) initiated Buy at Johnson Rice; PT USD 35.00
  • FuelCell Energy (FCEL) initiated Equal Weight at Barclays; PT USD 20.00
  • Energy Services of America (ESOA) initiated Buy at Roth/MKM; PT USD 20.00
  • Eupraxia Pharmaceuticals (EPRX) initiated Outperform at Wedbush; PT USD 17.00
  • California Water Service Group (CWT) initiated Hold at Freedom Broker; PT USD 49.00
  • Contineum Therapeutics (CTNM) initiated Early-Stage Biotech at Goldman Sachs
  • The Carlyle Group (CG) initiated Overweight at Piper Sandler; PT USD 54.00
  • CNB Financial (CCNE) initiated Overweight at Piper Sandler; PT USD 38.00
  • BlueLinx (BXC) initiated Market Perform at Citizens
  • Brink's (BCO) initiated Outperform at Wolfe Research; PT USD 138.00
  • Arrowhead Pharmaceuticals (ARWR) initiated Neutral at Goldman Sachs; PT USD 74.00
  • Ares Management (ARES) initiated Overweight at Piper Sandler; PT USD 150.00
  • Alkermes (ALKS) initiated Neutral at Goldman Sachs; PT USD 50.00
  • AbCellera Biologics (ABCL) initiated Neutral at Goldman Sachs; PT USD 13.00
Context

The JPMorgan actions amount to a sector-wide REIT reshuffle, with upgrades across healthcare, industrial and mall exposure offset by downgrades in gaming, office and retail names, the kind of batch move that typically reflects a published sector view rather than name-specific calls and tends to be read as a relative-value signal within the group. The Goldman initiations across a broad slate of biotech and pharma names signal a coverage launch in that space, which historically draws more attention to the Sell-rated outliers than to the buys. The CoreWeave and Nebius upgrades sit in the AI infrastructure complex, where single-bank calls have tended to move these high-beta names more than comparable calls elsewhere, though the effect usually fades without follow-through from peers. Items of this kind are market color, not signal, unless they cluster: the follow-on worth noting is whether other houses echo the JPMorgan REIT stance or the biotech Sells, since convergent revisions are what have historically sustained moves beyond the session. Standalone rating changes from a single house have a well-established pattern of gap-and-fade in large caps, with more durability in thinly covered small caps.

Related headlines

The whole workspace, free to try.

Try it free